{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.005%25+Latanoprost+Ophthalmic+Solution",
    "query": {
      "intervention": "0.005% Latanoprost Ophthalmic Solution"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 58,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.005%25+Latanoprost+Ophthalmic+Solution&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T13:45:24.576Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00868894",
      "title": "Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "DE-104 medium concentration",
          "type": "DRUG"
        },
        {
          "name": "DE-104 high concentration",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "0.005% latanoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2009-03",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2011-11-03",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 6,
      "location_summary": "Artesia, California • Pasadena, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Kailua",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00868894"
    },
    {
      "nct_id": "NCT04630808",
      "title": "MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "NCX 470 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicox Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 696,
      "start_date": "2020-11-09",
      "completion_date": "2025-06-25",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 63,
      "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04630808"
    },
    {
      "nct_id": "NCT00847483",
      "title": "Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "latanoprost 0.005% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Travoprost 004% sterile ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost .03% sterile ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2002-01",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 40,
      "location_summary": "Bellflower, California • Inglewood, California • San Diego, California + 31 more",
      "locations": [
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00847483"
    },
    {
      "nct_id": "NCT06964191",
      "title": "Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "PA5108 Ocular Implant low dose",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PA5108 Ocular Implant, high dose",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "PolyActiva Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2025-05-31",
      "completion_date": "2026-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06964191"
    },
    {
      "nct_id": "NCT00705757",
      "title": "The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Application Site Pigmentation Changes"
      ],
      "interventions": [
        {
          "name": "latanoprost",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost",
          "type": "DRUG"
        },
        {
          "name": "travoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Summa Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2008-03",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2016-01-18",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 2,
      "location_summary": "Arlington Heights, Illinois • Akron, Ohio",
      "locations": [
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00705757"
    },
    {
      "nct_id": "NCT00650338",
      "title": "Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "DE-104 ophthalmic solution, low concentration",
          "type": "DRUG"
        },
        {
          "name": "DE-104 ophthalmic solution, medium concentration",
          "type": "DRUG"
        },
        {
          "name": "DE-104 ophthalmic solution, high concentration",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "0.005% latanoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2008-03",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2011-11-03",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 14,
      "location_summary": "Artesia, California • Los Angeles, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        },
        {
          "city": "Bel Air",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00650338"
    },
    {
      "nct_id": "NCT03216902",
      "title": "A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma, Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical ultra-low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical medium dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "0.005% Latanoprost Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2017-07-25",
      "completion_date": "2018-02-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-23",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 12,
      "location_summary": "Artesia, California • Mission Hills, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03216902"
    },
    {
      "nct_id": "NCT01253902",
      "title": "Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost ophthalmic solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "travoprost ophthalmic solution 0.004%",
          "type": "DRUG"
        },
        {
          "name": "latanoprost ophthalmic solution 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2010-12",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-07",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 1,
      "location_summary": "Rogers, Arkansas",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253902"
    },
    {
      "nct_id": "NCT03657797",
      "title": "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Hypertension, Ocular"
      ],
      "interventions": [
        {
          "name": "NCX 470",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicox Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 656,
      "start_date": "2018-08-01",
      "completion_date": "2019-08-23",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657797"
    },
    {
      "nct_id": "NCT04445519",
      "title": "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "NCX 470 0.065% (initial phase of trial)",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% (initial phase of trial)",
          "type": "DRUG"
        },
        {
          "name": "NCX 470 0.1% (initial phase of trial)",
          "type": "DRUG"
        },
        {
          "name": "NCX 470 0.1% (remainder of trial)",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% (remainder of trial)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicox Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 691,
      "start_date": "2020-06-01",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-10-01T13:45:24.576Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04445519"
    }
  ]
}